[logo] HealthTree Foundation
search person

Clinical Trial: Ibrutinib with Pomalidomide and Dexamethasone for Relapsed/Refractory Myeloma Patients

Posted: Mar 06, 2017
Clinical Trial: Ibrutinib with Pomalidomide and Dexamethasone for Relapsed/Refractory Myeloma Patients image
link icon facebook logo X logo linkedin logo reddit logo email icon
Ibrutinib is a new drug being studied to treat myeloma and is a Bruton's Tyrosine Kinase (BTK) Inhibitor. The drug targets BTK, an enzyme necessary for the development of fully functional B-cells. The BTK enzyme is known to be more prolific in cancerous B-cells.  Malignant myeloma cells have increased BTK expression compared to non-malignant cells, so blocking BTK activity in myeloma has been shown to inhibit growth of tumors and release of osteoclast-derived tumor growth factors. Ibrutinib has been studied since the 1990's and has been used in many clinical trial in the last few years. 

A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)

The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:

  • Ibrutinib/pomalidomide/dex
  • Placebo/pomalidomide/dex

There are 5 locations for this trial. 

To find the clinical trial on SparkCures, click here:

Ibrutinib/Pom/Dex Clinical Trial

Ibrutinib is a new drug being studied to treat myeloma and is a Bruton's Tyrosine Kinase (BTK) Inhibitor. The drug targets BTK, an enzyme necessary for the development of fully functional B-cells. The BTK enzyme is known to be more prolific in cancerous B-cells.  Malignant myeloma cells have increased BTK expression compared to non-malignant cells, so blocking BTK activity in myeloma has been shown to inhibit growth of tumors and release of osteoclast-derived tumor growth factors. Ibrutinib has been studied since the 1990's and has been used in many clinical trial in the last few years. 

A Phase I clinical trial will study a new drug called ibrutinib in combination with pomalidomide (an immunomodulator) and dexamathasone (a steroid.)

The Phase II study will be divided into two groups for relapsed/refractory myeloma patients:

  • Ibrutinib/pomalidomide/dex
  • Placebo/pomalidomide/dex

There are 5 locations for this trial. 

To find the clinical trial on SparkCures, click here:

Ibrutinib/Pom/Dex Clinical Trial

The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can contribute to cures by joining HealthTree Cure Hub and joining clinical research. Founder and CEO of HealthTree Foundation. 

More on Navigating Your Health

CAR-T therapy and secondary hematological malignancies image
CAR-T therapy and secondary hematological malignancies
Underdiagnosed Anxiety and Depression in Lymphoma and Myeloma image
Underdiagnosed Anxiety and Depression in Lymphoma and Myeloma
How Substance Use Impacts Cancer Care: Breaking the Stigma to Improve Patient Outcomes image
How Substance Use Impacts Cancer Care: Breaking the Stigma to Improve Patient Outcomes
Anxious About Your Myeloma Exams? You Are Not Alone: Learn What Scanxiety Is image
Anxious About Your Myeloma Exams? You Are Not Alone: Learn What Scanxiety Is
Understanding and Managing Brain-Related Side Effects of Blood Cancer Treatments image
Understanding and Managing Brain-Related Side Effects of Blood Cancer Treatments
Senate Committee Champions Biomedical Research Funding that Advances Cancer Care image
Senate Committee Champions Biomedical Research Funding that Advances Cancer Care
See More Navigating Your Health
Thanks to our sponsors:
Sanofi logo
Adaptive logo
Pfizer logo
GSK logo
newsletter icon

Get the Latest Multiple Myeloma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.

Education

News Articles Patient Guides My Journal University Expert Webinars Find a Specialist HealthTree Podcast

Community

Connect Coach Moves All Events Community Support Groups Black Myeloma Health Resources in Spanish

Cure Hub

HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial Finder

Get Involved

Join a Regional Cure Team Create a fundraiser Tribute Donate Patient Surveys & Studies Connect Medical Records All Publications HealthTree Research Initiative

About us

Our Story HealthTree in The News Annual Reports

Need Help?

Contact Us FAQ & Help Center 1-800-709-1113

Legal Info

Terms of Use Privacy Policy

Follow Us

facebook instagram linkedin tiktok youtube
Download our App
Download iOS App Download Android App

Charity Navigator https://www.guidestar.org/profile/45-5354811

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2025 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811